Rafael Molina

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Concepts & Ideas

Disorders

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Molina Rafael; Augé Josep M; Bosch Xavier; Escudero José M; Viñolas Nuria; Marrades Ramón; Ramírez José; Carcereny Enric; Filella Xavier
Usefulness of serum tumor markers, including progastrin-releasing peptide, in patients with lung cancer: correlation with histology.
Domingo-Domenech J; Fernandez P L; Filella X; Martinez-Fernandez A; Molina R; Fernandez E; Alcaraz A; Codony J; Gascon P; Mellado B
Serum HER2 extracellular domain predicts an aggressive clinical outcome and biological PSA response in hormone-independent prostate cancer patients treated with docetaxel.
Molina Rafael; Auge Jose Maria; Escudero Jose Miguel; Marrades Ramon; Viñolas Nuria; Carcereny Emilio; Ramirez Jose; Filella Xavier
Mucins CA 125, CA 19.9, CA 15.3 and TAG-72.3 as tumor markers in patients with lung cancer: comparison with CYFRA 21-1, CEA, SCC and NSE.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Rafael Molina (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Molina Rafael; Augé Josep M; Bosch Xavier; Escudero José M; Viñolas Nuria; Marrades Ramón; Ramírez José; Carcereny Enric; Filella Xavier
Usefulness of serum tumor markers, including progastrin-releasing peptide, in patients with lung cancer: correlation with histology.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2009;30(3):121-9.
2008: Domingo-Domenech J; Fernandez P L; Filella X; Martinez-Fernandez A; Molina R; Fernandez E; Alcaraz A; Codony J; Gascon P; Mellado B
Serum HER2 extracellular domain predicts an aggressive clinical outcome and biological PSA response in hormone-independent prostate cancer patients treated with docetaxel.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19(2):269-75.
2008: Molina Rafael; Auge Jose Maria; Escudero Jose Miguel; Marrades Ramon; Viñolas Nuria; Carcereny Emilio; Ramirez Jose; Filella Xavier
Mucins CA 125, CA 19.9, CA 15.3 and TAG-72.3 as tumor markers in patients with lung cancer: comparison with CYFRA 21-1, CEA, SCC and NSE.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2008;29(6):371-80.
2008: Molina Rafael; Gion Massimo; Gressner Axel; Troalen Frédéric; Auge Jose Maria; Holdenrieder Stefan; Zancan Matelda; Wycislo Matthias; Stieber Petra
Alternative antibody for the detection of CA15-3 antigen: a European multicenter study for the evaluation of the analytical and clinical performance of the Access BR Monitor assay on the UniCel Dxl 800 Immunoassay System.
Clinical chemistry and laboratory medicine : CCLM / FESCC 2008;46(5):612-22.
2008: Stieber Petra; Molina Rafael; Gion Massimo; Gressner Axel; Troalen Frédéric; Holdenrieder Stefan; Auge Jose Maria; Zancan Matelda; Wycislo Matthias; Jarrige Véronique
Alternative antibody for the detection of CA19-9 antigen: a European multicenter study for the evaluation of the analytical and clinical performance of the Access GI Monitor assay on the UniCel Dxl 800 Immunoassay System.
Clinical chemistry and laboratory medicine : CCLM / FESCC 2008;46(5):600-11.
2008: Holdenrieder Stefan; Molina Rafael; Gion Massimo; Gressner Axel; Troalen Frédéric; Auge Jose Maria; Zancan Matelda; Wycislo Matthias; Stieber Petra
Alternative antibody for the detection of CA125 antigen: a European multicenter study for the evaluation of the analytical and clinical performance of the Access OV Monitor assay on the UniCel Dxl 800 Immunoassay System.
Clinical chemistry and laboratory medicine : CCLM / FESCC 2008;46(5):588-99.
2007: Maurel Joan; Nadal Cristina; Garcia-Albeniz Xabier; Gallego Rosa; Carcereny Enric; Almendro Vanesa; Mármol Maribel; Gallardo Elena; Maria Augé Josep; Longarón Raquel; Martínez-Fernandez Alex; Molina Rafael; Castells Antoni; Gascón Pere
Serum matrix metalloproteinase 7 levels identifies poor prognosis advanced colorectal cancer patients.
International journal of cancer. Journal international du cancer 2007;121(5):1066-71.
2007: Mas Sergi; Lafuente M Jose; Crescenti Anna; Trias Manuel; Ballesta Antonio; Molina Rafael; Zheng Shichun; Wiencke John K; Lafuente Amalia
Lower specific micronutrient intake in colorectal cancer patients with tumors presenting promoter hypermethylation in p16(INK4a), p4(ARF) and hMLH1.
Anticancer research 2007;27(2):1151-6.
2007: Filella Xavier; Alcover Joan; Molina Rafael; Luque Pilar; Corral Juan M; Augé Josep M; Coca Francisca
Usefulness of proprostate-specific antigen in the diagnosis of prostate cancer.
Anticancer research 2007;27(1B):607-10.
2007: Cao M González; Auge J M; Molina R; Martí R; Carrera C; Castel T; Vilella R; Conill C; Sánchez M; Malvehy J; Puig S
Melanoma inhibiting activity protein (MIA), beta-2 microglobulin and lactate dehydrogenase (LDH) in metastatic melanoma.
Anticancer research 2007;27(1B):595-9.
2007: Domingo-Domènech Josep; Castel Teresa; Auge Josep Maria; Garcia-Albeniz Xabier Adrian; Conill Carles; Puig Susana; Vilella Ramon; Matas Jose; Malvehy Josep; Gascón Pere; Mellado Begoña; Molina Rafael
Prognostic implications of protein S-100beta serum levels in the clinical outcome of high-risk melanoma patients.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2007;28(5):264-72.
2007: Mas Sergi; Crescenti Anna; Gassó Patricia; Deulofeu Ramon; Molina Rafael; Ballesta Antonio; Kensler Thomas W; Lafuente Amalia
Induction of apoptosis in HT-29 cells by extracts from isothiocyanates-rich varieties of Brassica oleracea.
Nutrition and cancer 2007;58(1):107-14.
2005: Molina Rafael; Barak Vivian; van Dalen Arie; Duffy Michael J; Einarsson Roland; Gion Massimo; Goike Helenka; Lamerz Rolf; Nap Marius; Sölétormos György; Stieber Petra
Tumor markers in breast cancer- European Group on Tumor Markers recommendations.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2005;26(6):281-93.
2005: Mas Sergi; Crescenti Anna; Vidal-Taboada Jose M; Bergoñon Salvador; Cuevillas Fernando; Laso Nuria; Molina Rafael; Ballesta Antonio; Lafuente Amalia
Simultaneous genotyping of CYP2C9*2, *3, and 5' flanking region (C-1189T) polymorphisms in a Spanish population through a new minisequencing multiplex single-base extension analysis.
European journal of clinical pharmacology 2005;61(9):635-41.
2005: Nadal Cristina; Maurel Joan; Gallego Rosa; Castells Antoni; Longarón Raquel; Marmol Maribel; Sanz Sergi; Molina Rafael; Martin-Richard Marta; Gascón Pere
FAS/FAS ligand ratio: a marker of oxaliplatin-based intrinsic and acquired resistance in advanced colorectal cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(13):4770-4.
2005: Auge J M; Molina R; Filella X; Bosch E; Gonzalez Cao M; Puig S; Malvehy J; Castel T; Ballesta A M
S-100beta and MIA in advanced melanoma in relation to prognostic factors.
Anticancer research 2005;25(3A):1779-82.
2005: Molina Rafael; Auge Jose M; Filella Xavier; Viñolas Nuria; Alicarte Julian; Domingo Jose M; Ballesta Antonio M
Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer.
Anticancer research 2005;25(3A):1773-8.
2005: Molina Rafael; Filella Xavier; Augé Jose M; Bosch Elvira; Torne Aureli; Pahisa Jaume; Lejarcegui Jose A; Rovirosa Angels; Mellado Begoña; Ordi Jaume; Biete Albert
CYFRA 21.1 in patients with cervical cancer: comparison with SCC and CEA.
Anticancer research 2005;25(3A):1765-71.
2005: Laso Nuria; Mas Sergi; Lafuente M Jose; Llobet Joan M; Molina Rafael; Ballesta Antonio; Kensler Thomas W; Lafuente Amalia
Induction of NAD(P)H quinone oxidoreductase by vegetables widely consumed in Catalonia, Spain.
Nutrition and cancer 2005;52(1):49-58.
2005: Domingo-Domènech J; Molina R; Castel T; Montagut C; Puig S; Conill C; Martí R; Vera M; Auge J M; Malvehy J; Grau J J; Gascon P; Mellado B
Serum protein s-100 predicts clinical outcome in patients with melanoma treated with adjuvant interferon--comparison with tyrosinase rt-PCR.
Oncology 2005;68(4-6):341-9.
2004: Filella Xavier; Truan David; Alcover Joan; Gutierrez Rafael; Molina Rafael; Coca Francisca; Ballesta Antonio M
Complexed prostate-specific antigen for the detection of prostate cancer.
Anticancer research 2004;24(6):4181-5.
2004: Molina Rafael; Filella Xavier; Augé Josep M
ProGRP: a new biomarker for small cell lung cancer.
Clinical biochemistry 2004;37(7):505-11.
2004: Filella Xavier; Truan David; Alcover Joan; Quintó Llorenç; Molina Rafael; Luque Pilar; Coca Francisca; Ballesta Antonio M
Comparison of several combinations of free, complexed, and total PSA in the diagnosis of prostate cancer in patients with urologic symptoms.
Urology 2004;63(6):1100-3; discussion 1103-4.
2004: Laso Nuria; Mas Sergi; Jose Lafuente M; Casterad Xavier; Trias Manuel; Ballesta Antonio; Molina Rafael; Salas Jordi; Ascaso Carlos; Zheng Shichun; Wiencke John K; Lafuente Amalia
Decrease in specific micronutrient intake in colorectal cancer patients with tumors presenting Ki-ras mutation.
Anticancer research 2004;24(3b):2011-20.
2004: Filella Xavier; Truan David; Alcover Joan; Molina Rafael; Luque Pilar; Coca Francisca; Ballesta Antonio M
[Usefulness of PSA and its fractions in the diagnosis of prostate cancer]
Medicina clínica 2004;122(7):241-4.
2004: Molina Rafael; Auge Jose M; Alicarte Julian; Filella Xavier; Viñolas Nuria; Ballesta Antonio M
Pro-gastrin-releasing peptide in patients with benign and malignant diseases.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2004;25(1-2):56-61.
2003: Molina R; Filella X; Augé J M; Fuentes R; Bover I; Rifa J; Moreno V; Canals E; Viñolas N; Marquez A; Barreiro E; Borras J; Viladiu P
Tumor markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis. Comparison with the main clinical and pathological prognostic factors.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2003;24(4):209-18.
2003: Miret Carlos; Molina Rafael; Filella Xavier; García-Carrasco Mario; Claver Gisela; Ingelmo Miguel; Ballesta Antonio; Font José
Relationship of p53 with other oncogenes, cytokines and systemic lupus erythematosus activity.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2003;24(4):185-8.
2003: Molina Rafael; Filella Xavier; Lejarcegui Jose A; Pahisa Jaime; Torné Aurelio; Rovirosa Angels; Mellado Begoña; Ordi Jaume; Puig-Tintore Luis M; Alicarte Julian; Biete Alberto; Iglesias Javier
Prospective evaluation of squamous cell carcinoma and carcinoembryonic antigen as prognostic factors in patients with cervical cancer.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2003;24(3):156-64.
2003: Molina R; Filella X; Zanon G; Pahisa J; Alicarte J; Munoz M; Farrus B; Ballesta A M
Prospective evaluation of tumor markers (c-erbB-2 oncoprotein, CEA and CA 15.3) in patients with locoregional breast cancer.
Anticancer research 2003;23(2A):1043-50.
2003: Molina R; Filella X; Alicarte J; Zanon G; Pahisa J; Munoz M; Farrus B; Ballesta A M
Prospective evaluation of CEA and CA 15.3 in patients with locoregional breast cancer.
Anticancer research 2003;23(2A):1035-41.
2003: Mas Sergi; Laso Nuria; Lafuente Maria Jose; Lafuente Amalia; Molina Rafael; Ballesta Antonio; Zheng Shichun; Wiencke John Kevin
Cancer, genes, and catechol estrogen metabolites.
International journal of clinical oncology / Japan Society of Clinical Oncology 2003;8(1):65-6.
2002: Laso N; Lafuente M J; Mas S; Trias M; Ascaso C; Molina R; Ballesta A; Rodriguez F; Lafuente A
Glutathione S-transferase (GSTM1 and GSTT1)-dependent risk for colorectal cancer.
Anticancer research 2002;22(6A):3399-403.
2002: Gibanel R; Ribal M J; Filella X; Ballesta A M; Molina R; Alcaraz A; Alcover J B
BTA TRAK urine test increases the efficacy of cytology in the diagnosis of low-grade transitional cell carcinoma of the bladder.
Anticancer research 2002;22(2B):1157-60.
2002: Molina Rafael; Navarro Javier; Filella Xavier; Castel Teresa; Ballesta Antonio Manuel
S-100 protein serum levels in patients with benign and malignant diseases: false-positive results related to liver and renal function.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2002;23(1):39-44.
2001: Filella X; Alcover J; Corral J M; Molina R; Beardo P; Ballesta A M
Free to complexed PSA ratio in differentiating benign prostate hyperplasia from prostate cancer.
Anticancer research 2001;21(5):3717-20.
2001: Miret C; Font J; Molina R; Garcia-Carrasco M; Filella X; Ramos M; Cervera R; Ballesta A; Ingelmo M
Relationship of oncogenes (sFas, Bcl-2) and cytokines (IL-10, alfa-TNF) with the activity of systemic lupus erythematosus.
Anticancer research 2001;21(4B):3053-9.
2001: Filella X; Molina R; Alcover J; Coca F; Zarco M A; Ballesta A M
Influence of AFP, CEA and PSA on the in vitro production of cytokines.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2001;22(2):67-71.
2000: van Dalen A; Favier J; Burges A; Hasholzner U; de Bruijn H W; Dobler-Girdziunaite D; Dombi V H; Fink D; Giai M; McGing P; Harlozinska A; Kainz C; Markowska J; Molina R; Sturgeon C; Bowman A; Einarsson R
Prognostic significance of CA 125 and TPS levels after 3 chemotherapy courses in ovarian cancer patients.
Gynecologic oncology 2000;79(3):444-50.
2000: Van Dalen A; Favier J; Baumgartner L; Hasholzner U; De Bruijn H; Dobbler D; Dombi V H; Fink D; Giai M; McGing P; Harlozinska A; Kainz C; Markowska J; Molina R; Sturgeon C; Bowman A; Einarsson R
Serum levels of CA 125 and TPS during treatment of ovarian cancer.
Anticancer research 2000;20(6D):5107-8.
2000: Lafuente M J; Casterad X; Trias M; Ascaso C; Molina R; Ballesta A; Zheng S; Wiencke J K; Lafuente A
NAD(P)H:quinone oxidoreductase-dependent risk for colorectal cancer and its association with the presence of K-ras mutations in tumors.
Carcinogenesis 2000;21(10):1813-9.
2000: Filella X; Alcover J; Zarco M A; Beardo P; Molina R; Ballesta A M
Analysis of type T1 and T2 cytokines in patients with prostate cancer.
The Prostate 2000;44(4):271-4.
2000: Menendez V; Filella X; Alcover J A; Molina R; Mallafre J M; Ballesta A M; Talbot-Wright R
Usefulness of urinary nuclear matrix protein 22 (NMP22) as a marker for transitional cell carcinoma of the bladder.
Anticancer research 2000;20(2B):1169-72.
2000: Filella X; Alcover J; Molina R; Corral J M; Carretero P; Ballesta A M
Measurement of complexed PSA in the differential diagnosis between prostate cancer and benign prostate hyperplasia .
The Prostate 2000;42(3):181-5.
1999: Filella X; Alcover J; Quintó L; Molina R; Bosch-Capblanch X; Carretero P; Ballesta A M
Evaluation of a multivariate prostate-specific antigen and percentage of free prostate-specific antigen logistic regression model in the diagnosis of prostate cancer.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 1999;20(6):312-8.
1999: Miret C; Font J; Molina R; Garcia-Carrasco M; Filella X; Ramos M; Cervera R; Ballesta A; Ingelmo M
Bcl-2 oncogene (B cell lymphoma/leukemia-2) levels correlate with systemic lupus erythematosus disease activity.
Anticancer research 1999;19(4B):3073-6.
1999: Molina R; Farrus B; Filella X; Jo J; Zanón G; Pahisa J; Latre M; Muñoz M; Ballesta A M
Carcinoembryonic antigen in tissue and serum from breast cancer patients relationship with steroid receptors and clinical applications in the prognosis and early diagnosis of relapse.
Anticancer research 1999;19(4A):2557-62.
1999: Molina R; Jo J; Filella X; Zanón G; Farrus B; Muñoz M; Latre M L; Pahisa J; Velasco M; Fernandez P; Estapé J; Ballesta A M
C-erbB-2, CEA and CA 15.3 serum levels in the early diagnosis of recurrence of breast cancer patients.
Anticancer research 1999;19(4A):2551-5.
1999: van Dalen A; Favier J; Baumgartner L; Hasholzner U; de Bruijn H; Dobbler D; Dombi V H; Fink D; Giai M; McGing P; Harlozinska A; Kainz C; Markowska J; Molina R; Sturgeon C; Einarsson R
Prognostic significance of CA 125 and TPS levels after chemotherapy in ovarian cancer patients.
Anticancer research 1999;19(4A):2523-6.
1998: Filella X; Bladé J; Montoto S; Molina R; Coca F; Montserrat E; Ballesta A M
Impaired production of interleukin 6 and tumour necrosis factor alpha in whole blood cell cultures of patients with multiple myeloma.
Cytokine 1998;10(12):993-6.
1998: Molina R; Filella X; Jo J; Agusti C; Ballesta A M
CA 125 in biological fluids.
The International journal of biological markers 1998;13(4):224-30.
1998: Molina R; Jo J; Filella X; Zanon G; Pahisa J; Mu noz M; Farrus B; Latre M L; Escriche C; Estape J; Ballesta A M
c-erbB-2 oncoprotein, CEA, and CA 15.3 in patients with breast cancer: prognostic value.
Breast cancer research and treatment 1998;51(2):109-19.
1998: Lafuente A; Rodriguez A; Gibanel R; Lafuente M J; Alonso M; Molina R; Ballesta A; Carretero P
Limitations in the use of glutathione S-transferase P1 in urine as a marker for bladder cancer.
Anticancer research 1998;18(5B):3771-2.
1998: Miret C; Font J; Molina R; Filella X; Vivancos J; Muñoz-Rodriguez F J; Cervera R; Ballesta A M; Ingelmo M
Lack of correlation between tumor markers (CA 125 and SCC) and systemic lupus erythematosus activity.
Anticancer research 1998;18(2B):1341-4.
1998: Van Dalen A; Barak V; Cremaschi A; Gion M; Molina R; Namer M; Stieber P; Sturgeon C; Einarsson R
The prognostic significance of increasing marker levels in metastatic breast cancer patients with clinically complete remission, partial remission or stable disease.
The International journal of biological markers 1998;13(1):10-5.
1998: Viñolas N; Molina R; Galán M C; Casas F; Callejas M A; Filella X; Grau J J; Ballesta A M; Estape J
Tumor markers in response monitoring and prognosis of non-small cell lung cancer: preliminary report.
Anticancer research 1998;18(1B):631-4.
1998: Molina R; Segui M A; Climent M A; Bellmunt J; Albanelll J; Fernandez M; Filella X; Jo J; Gimenez N; Iglesias E; Miralles M; Alonso C; Peiro G; Perez-Picañol E; Ballesta A M
p53 oncoprotein as a prognostic indicator in patients with breast cancer.
Anticancer research 1998;18(1B):507-11.
1998: Lafuente A; Maristany M; Arias C; Cuchi A; Lafuente M J; Molina R; Ballesta A; Trasserra J
Glutathione and glutathione S-transferases in human squamous cell carcinomas of the larynx and GSTM1 dependent risk.
Anticancer research 1998;18(1A):107-11.
1997: Filella X; Alcover J; Molina R; Rodríguez A; Carretero P; Ballesta A M
Clinical evaluation of free PSA/total PSA (prostate-specific antigen) ratio in the diagnosis of prostate cancer.
European journal of cancer (Oxford, England : 1990) 1997;33(8):1226-9.
1997: Moral A; Palou J; Lafuente A; Molina R; Piulachs J; Castel T; Trias M
Immunohistochemical study of alpha, mu and pi class glutathione S transferase expression in malignant melanoma. MMM Group. Multidisciplinary Malignant Melanoma Group.
The British journal of dermatology 1997;136(3):345-50.
1997: Filella X; Alcover J; Molina R; Rodríguez A; Carretero P; Ballesta A M
Free and total PSA in the diagnosis of prostate cancer.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 1997;18(6):332-40.
1997: Molina R; Jo J; Filella X; Bruix J; Castells A; Hague M; Ballesta A M
Serum levels of C-erbB-2 (HER-2/neu) in patients with malignant and non-malignant diseases.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 1997;18(3):188-96.
1997: Durany N; Joseph J; Campo E; Molina R; Carreras J
Phosphoglycerate mutase, 2,3-bisphosphoglycerate phosphatase and enolase activity and isoenzymes in lung, colon and liver carcinomas.
British journal of cancer 1997;75(7):969-77.
1996: Filella X; Molina R; Alcover J; Carretero P; Ballesta A M
Detection of nonprostatic PSA in serum and nonserum samples from women.
International journal of cancer. Journal international du cancer 1996;68(4):424-7.
1996: Filella X; Molina R; Alcover J; Menéndez V; Giménez N; Jo J; Carretero P; Ballesta A M
Prostate-specific antigen detection by ultrasensitive assay in samples from women.
The Prostate 1996;29(5):311-6.
1996: Molina R; Jo J; Zanón G; Filella X; Farrus B; Muñoz M; Latre M L; Pahisa J; Velasco M; Fernandez P; Estapé J; Ballesta A M
Utility of C-erbB-2 in tissue and in serum in the early diagnosis of recurrence in breast cancer patients: comparison with carcinoembryonic antigen and CA 15.3.
British journal of cancer 1996;74(7):1126-31.
1996: Molina R; Jo J; Filella X; Zanon G; Pahisa J; Muñoz M; Farrus B; Latre M L; Gimenez N; Hage M; Estape J; Ballesta A M
C-erbB-2 oncoprotein in the sera and tissue of patients with breast cancer. Utility in prognosis.
Anticancer research 1996;16(4B):2295-300.
1996: Filella X; Menendez V; Molina R; Alcover J; Carretero P; Ballesta A M
TPA prognostic value in superficial bladder cancer.
Anticancer research 1996;16(4B):2173-5.
1996: Filella X; Ballesta A M; Fox M; Mitchell H; Molina R; Pürstner P; Thome H
Multicentre clinical evaluation of the COBAS CORE CEA, CA 125 II and PSA tumor marker assays.
The International journal of biological markers 1996;11(1):40-5.
1996: Molina R; Torres M D; Moragas M; Perez-Villa J; Filella X; Jo J; Farrus B; Giménez N; Traserra J; Ballesta A M
Prognostic significance of SCC antigen in the serum of patients with head and neck cancer.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 1996;17(2):81-9.
1996: Filella X; Alcover J; Molina R; Carrere W; Carretero P; Ballesta A M
Usefulness of prostate-specific antigen density as a diagnostic test of prostate cancer.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 1996;17(1):20-6.
1995: Filella X; Alcover J; Molina R; Giménez N; Rodríguez A; Jo J; Carretero P; Ballesta A M
Clinical usefulness of free PSA fraction as an indicator of prostate cancer.
International journal of cancer. Journal international du cancer 1995;63(6):780-4.
1995: Lafuente A; Molina R; Palou J; Castel T; Moral A; Trias M
Phenotype of glutathione S-transferase Mu (GSTM1) and susceptibility to malignant melanoma. MMM group. Multidisciplinary Malignant Melanoma Group.
British journal of cancer 1995;72(2):324-6.
1995: Menéndez V; Filella X; Alcover J; Molina R; Ballesta A M; Carretero P
[Role of tissue polypeptide antigen as a marker in bladder cancer]
Actas urologicas españolas 1995;19(6):441-4.
1995: Borras G; Molina R; Xercavins J; Ballesta A; Iglesias J
Tumor antigens CA 19.9, CA 125, and CEA in carcinoma of the uterine cervix.
Gynecologic oncology 1995;57(2):205-11.
1995: Molina R; Torres M D; Moragas M; Filella X; Jo J; Giménez N; Traserra J; Ballesta A M
Prognostic value of TPS in patients with head and neck malignancies: comparison with SCC.
Anticancer research 1995;15(2):479-84.
1995: Ballesta A M; Molina R; Filella X; Jo J; Giménez N
Carcinoembryonic antigen in staging and follow-up of patients with solid tumors.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 1995;16(1):32-41.
1995: Molina R; Zanón G; Filella X; Moreno F; Jo J; Daniels M; Latre M L; Giménez N; Pahisa J; Velasco M
Use of serial carcinoembryonic antigen and CA 15.3 assays in detecting relapses in breast cancer patients.
Breast cancer research and treatment 1995;36(1):41-8.
1994: Molina R; Agusti C; Mañe J M; Filella X; Jo J; Joseph J; Giménez N; Estapé J; Ballesta A M
CYFRA 21-1 in lung cancer: comparison with CEA, CA 125, SCC and NSE serum levels.
The International journal of biological markers 1994;9(2):96-101.
1994: Filella X; Molina R; Piqué J M; Grau J J; Garcia-Valdecasas J C; Biete A; Novell F; Astudillo E; Bordas J M; Campo E
CEA as a prognostic factor in colorectal cancer.
Anticancer research 1994;14(2B):705-8.
1994: Filella X; Molina R; Piqué J M; Garcia-Valdecasas J C; Grau J J; Novell F; Astudillo E; de Lacy A; Daniels M; Ballesta A M
Use of CA 19-9 in the early detection of recurrences in colorectal cancer: comparison with CEA.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 1994;15(1):1-6.
1994: Molina R; Agusti C; Filella X; Jo J; Joseph J; Giménez N; Ballesta A M
Study of a new tumor marker, CYFRA 21-1, in malignant and nonmalignant diseases.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 1994;15(6):318-25.
1994: Filella X; Fuster J; Molina R; Grau J J; García-Valdecasas J C; Grande L; Estapé J; Ballesta A M
TAG-72, CA 19.9 and CEA as tumor markers in gastric cancer.
Acta oncologica (Stockholm, Sweden) 1994;33(7):747-51.
1993: Alcover J; Filella X; Barranco M A; Molina R; Ballesta A M; Carretero P
False positive values of PAP and PSA in complicated and non-complicated benign prostatic hypertrophy.
Archivio italiano di urologia, andrologia : organo ufficiale [di] Società italiana di ecografia urologica e nefrologica / Associazione ricerche in urologia 1993;65(6):657-60.
1993: Molina R; Filelia X; Segui M A; Climent M A; Pérez-Picañol E; Alonso C; Jo J; Ojeda B; Tandon A K; Ballesta A M
Oncogenic proteins and prognostic correlations in breast cancer.
In vivo (Athens, Greece) 1993;7(6B):585-9.
1993: Molina R; Jo J; Filella X; Zanon G; Grau J J; Joseph J; Bedini J L; Biete A; Ballesta A M
Mucin-like carcinoma-associated antigen (MCA) in tissue and serum of patients with breast cancer: clinical applications in prognosis and disease monitoring.
The International journal of biological markers 1993;8(2):113-23.
1992: Filella X; Molina R; Grau J J; Piqué J M; Garcia-Valdecasas J C; Astudillo E; Biete A; Bordas J M; Novell A; Campo E
Prognostic value of CA 19.9 levels in colorectal cancer.
Annals of surgery 1992;216(1):55-9.
1992: Borras G; Molina R; Xercavins J; Ballesta A; Iglesias X
Squamous cell carcinoma antigen in cervical cancer.
European journal of gynaecological oncology 1992;13(5):414-8.
1992: Filella X; Molina R; Jo J; Bedini J L; Joseph J; Ballesta A M
Tumor associated glycoprotein-72 (TAG-72) levels in patients with non-malignant and malignant disease.
Bulletin du cancer 1992;79(3):271-7.
1992: Molina R; Ojeda B; Filella X; Borras G; Jo J; Mas E; Lopez J J; Ballesta A
A prospective study of tumor markers CA 125 and CA 19.9 in patients with epithelial ovarian carcinomas.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 1992;13(5-6):278-86.
1991: Molina R; Filella X; Bruix J; Mengual P; Bosch J; Calvet X; Jo J; Ballesta A M
Cancer antigen 125 in serum and ascitic fluid of patients with liver diseases.
Clinical chemistry 1991;37(8):1379-83.
1991: Filella X; Molina R; Mengual P J; Jo J; Ballesta A M
Significance of CA72.4 in patients with colorectal cancer. Comparison with CEA and CA19.9.
Journal of nuclear biology and medicine (Turin, Italy : 1991) 1991;35(3):158-61.
1991: Cases A; Filella X; Molina R; Ballesta A M; Lopez-Pedret J; Revert L
Tumor markers in chronic renal failure and hemodialysis patients.
Nephron 1991;57(2):183-6.
1991: Filella X; Molina R; Jo J; Mas E; Ballesta A M
Serum phosphohexose isomerase activities in patients with colorectal cancer.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 1991;12(6):360-7.
1990: Filella X; Molina R; Bedini J L; Jo J; Joseph J; Ballesta A M
Clinical usefulness of CEA as tumor marker in patients with colorectal cancer.
The Journal of nuclear medicine and allied sciences 1990;34(4 Suppl):107-10.
1990: Filella X; Cases A; Molina R; Jo J; Bedini J L; Revert L; Ballesta A M
Tumor markers in patients with chronic renal failure.
The International journal of biological markers 1990;5(2):85-8.
1990: Molina R; Filella X; Torres M D; Ballesta A M; Mengual P; Cases A; Balaque A
SCC antigen measured in malignant and nonmalignant diseases.
Clinical chemistry 1990;36(2):251-4.
1990: Molina R; Filella X; Mengual P; Prats M; Zanon G; Daniels M; Ballesta A M
MCA in patients with breast cancer: correlation with CEA and CA15-3.
The International journal of biological markers 1990;5(1):14-21.
1990: Molina R; Filella X; Herranz M; Prats M; Velasco A; Zanon G; Martinez-Osaba M J; Ballesta A M
Biochemistry of cyst fluid in fibrocystic disease of the breast. Approach to classification and understanding of the mechanism of formation.
Annals of the New York Academy of Sciences 1990;586():29-42.
1990: Filella X; Molina R; Jo J; Umbert B; Bedini J L; Ballesta A M
Clinical usefulness of prostate-specific antigen and prostatic acid phosphatase in patients with prostatic cancer.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 1990;11(6):289-94.
1989: Molina R; Santabarbara P; Filella X; Mengual P; Ballesta A M; Balague A
Relationship of CA 125 and CA 19.9 with lung carcinoma histological subtype: preliminary study.
The International journal of biological markers 1989;4(4):215-20.
1989: Bedini J L; Casals E; Sanllehy C; Filella X; Mas E; Molina R; Ballesta A M
A new immunonephelometric method for amniotic fluid alpha-fetoprotein measurement.
The Journal of nuclear medicine and allied sciences 1989;33(3 Suppl):135-7.
1988: Iglesias J; Borras G; Lailla J M; Fortuny A; Molina R; Ballesta A; Sentís J
Total LDH and its isoenzymes in gynecological malignancies and other gynecological conditions.
European journal of gynaecological oncology 1988;9(1):32-5.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Rafael Molina

Research Profile (preview)

Chemicals & Drugs

Concepts & Ideas

Disorders

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Rafael Molina (preview)

All Publications